弥漫大B细胞淋巴瘤(DLBCL)是非霍奇金淋巴瘤(NHL)最常见的亚型,病态,和具有高度可变的临床结果的分子异质性疾病。目前,目前仍缺乏有效的DLBCL预后标志物.优化靶向治疗,改善DLBCL的预后,建议的生物标志物的性能需要在多个队列中进行评估,新的生物标志物需要在大数据集中进行研究。这里,我们为弥漫性大B细胞淋巴瘤开发了一个一致的在线生存分析网络服务器,缩写为OSdlbcl,评估个体基因的预后价值。要构建OSdlbcl,我们从癌症基因组图谱(TCGA)和基因表达综合(GEO)数据库中收集了1100份具有基因表达谱和临床随访信息的样本.此外,还从TCGA数据库收集DNA突变数据。总生存期(OS),无进展生存期(PFS),疾病特异性生存率(DSS),无病间隔(DFI),无进展间期(PFI)是反映OSdlbcl生存率的重要终点。此外,将临床特征整合到OSdlbcl中,以便根据用户的特殊需要进行数据分层.通过输入官方基因符号并选择所需的标准,生存分析结果可以通过具有风险比(HR)和log-rankp值的Kaplan-Meier(KM)图以图形方式呈现。作为概念验证演示,先前报道的23种生存相关生物标志物的预后价值,在OSdlbcl中评估了转录因子FOXP1和BCL2,发现它们与所报告的生存率显着相关(HR=1.73,P<.01;HR=1.47,P=.03)。总之,OSdlbcl是一个新的网络服务器,集成了公共基因表达,基因突变数据,和临床随访信息,为DLBCL的生物标志物开发提供预后评估。OSdlbclWeb服务器可在https://bioinfo获得。henu.edu.cn/DLBCL/DLBCLList。jsp.
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL) and is a clinical, pathological, and molecular heterogeneous disease with highly variable clinical outcomes. Currently, valid prognostic biomarkers in DLBCL are still lacking. To optimize targeted therapy and improve the prognosis of DLBCL, the performance of proposed biomarkers needs to be evaluated in multiple cohorts, and new biomarkers need to be investigated in large datasets. Here, we developed a
consensus Online Survival analysis web server for Diffuse Large B-Cell Lymphoma, abbreviated OSdlbcl, to assess the prognostic value of individual gene. To build OSdlbcl, we collected 1100 samples with gene expression profiles and clinical follow-up information from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. In addition, DNA mutation data were also collected from the TCGA database. Overall survival (OS), progression-free survival (PFS), disease-specific survival (DSS), disease-free interval (DFI), and progression-free interval (PFI) are important endpoints to reflect the survival rate in OSdlbcl. Moreover, clinical features were integrated into OSdlbcl to allow data stratifications according to the user\'s special needs. By inputting an official gene symbol and selecting desired criteria, the survival analysis results can be graphically presented by the Kaplan-Meier (KM) plot with hazard ratio (HR) and log-rank p value. As a proof-of-concept demonstration, the prognostic value of 23 previously reported survival associated biomarkers, such as transcription factors FOXP1 and BCL2, was evaluated in OSdlbcl and found to be significantly associated with survival as reported (HR = 1.73, P < .01; HR = 1.47, P = .03, respectively). In conclusion, OSdlbcl is a new web server that integrates public gene expression, gene mutation data, and clinical follow-up information to provide prognosis evaluations for biomarker development for DLBCL. The OSdlbcl web server is available at https://bioinfo.henu.edu.cn/DLBCL/DLBCLList.jsp.